Fed: Gradual easing path under Warsh – UOB
UOB strategists Suan Teck Kin and Alvin Liew assess how a potential Kevin Warsh Fed chairmanship could shape United States (US) monetary policy and the Fed funds rate. They expect a pause through early 2026, then two cuts in June and 3Q, taking the Fed Funds Target Rate (FFTR) to 3.25% by end-2026, with risks from higher energy prices and labour softness.
UOB outlines cautious easing trajectory
"Expect gradual change, not shock therapy: FOMC consensus and the May leadership transition constrain abrupt policy shifts in the near term. Futures market is pricing in about 10bps cut to the Fed funds rate by Dec 2026. On our part, we still expect a Fed pause in early 2026 (including Apr FOMC), then two rate cuts in Jun and 3Q, taking FFTR to 3.25%."
"Where does this leave the Fed funds rate in the over 6 to 12 months? For the next FOMC meeting (30 Apr), financial markets and we do not expect any change to the current Fed funds rate of 3.5-3.75%, which is likely to be the final meeting for current Chair Jerome Powell."
"Over the next 6-9 months’ horizon, futures markets are pricing in an implied Fed funds rate of 3.54% at end-Dec 2026, meaning a cumulative rate reduction of approximately 10bps, i.e. a modest, gradual easing path rather than an aggressive one."
"As such, we continue to expect a period of pause (including the Apr FOMC) followed by two rate reductions in Jun and 3Q26, with the expectations for more visible weakness in the labour market and consumer spending to emerge in the months ahead."
"This would bring the terminal FFTR to 3.25% by year-end 2026, consistent with our view of a gradual normalization path."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.
